Research analyst, medium-term horizon, biotech, small-cap

Aastrom Digs In, Refocuses On DCM

It's been a difficult road for Aastrom Biosciences (ASTM) over the past two years, but management remains committed to its platform and sees potential with ixmyelocel-T in dialated cardiomyopathy (NYSE:DCM). We will find out if the strategy pays off in 2015.

Enrollment in the Phase 2 ixCELL-DCM study, initiated in April 2013, continues on plan. The company had previously generated strong proof-of-concept in DCM. A twelve month follow-up analysis from the company's phase 2a Catheter-DCM study was presented at the Society for Cardiovascular Angiography and Interventions (SCAI) in May 2012. Slides from this presentation can be found via this link. This was a 22 patient study designed to evaluate the safety and efficacy of intra-myocardial delivery of...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details